Chakshu Research Inc.
This article was originally published in Start Up
Executive Summary
Chakshu Research believes its drug candidate can interfere with the pathogenic processes that cause oxidative stress, which can, in turn, cause tissue damage. The company is developing a solution, made up of GRAS substances, designed to reduce the amount of reactive metal ions that act as a catalyst of harmful oxidative reactions in the eye, and thus treat cataracts and other ophthalmic disorders.